ALFA Finder
Thu, 5 Nov
Ipca Laboratories
Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
Summary ready
Earnings calls
Ipca Laboratories concalls
Every Ipca Laboratories earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
Outlook
Reiterated FY27 guidance: 14-16% revenue growth and 22-23% consolidated EBITDA margin, with no revision. Institutional sales may reach ₹325-340 Cr.
Earlier call summaries
All →
11:59 IST
BSE
Earnings Call
Ipca Laboratories Earnings Call Transcript: Key Takeaways
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
- Call
- Guides 16% growth
13:44 IST
BSE
Earnings Call
Ipca Laboratories Earnings Call: Key Takeaways
Ipca Labs reports 8% FY26 consolidated revenue growth to ₹9,646cr. Management focuses on margin improvement and volume-led growth in domestic and US markets.
Ipca Laboratories Ltd: key numbers
- Share price
- ₹1,943.30
- Market cap
- ₹49,302 Cr
- Revenue (annual)
- ₹9,646 Cr
- Net profit (annual)
- ₹1,141 Cr
- P/E (TTM)
- 35.2×Sector 43.8×
- Promoter holding
- 44.72%+0.00% QoQ
- FII holding
- 11.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.